{"title":"GLP-1R 激动剂度拉鲁肽和胃泌素受体类似物阿那莫瑞林在改善肌肉萎缩方面的协同潜力","authors":"Hla Myat Mo Mo , Jong Han Lee","doi":"10.1016/j.mehy.2024.111418","DOIUrl":null,"url":null,"abstract":"<div><p>Muscle atrophy represents a multifaceted and intricate syndrome characterized by the reduction in both mass and strength of skeletal muscles, leading to muscle dysfunction and weakness. Its potential causes encompass aging, denervation, disuse, and various diseases. One well-known pharmacological agent for glycemic control in diabetes patients is the glucagon-like peptide-1 receptor (GLP-1R) agonist. Our recent research findings have shown that compounds such as exendin-4 (Ex-4) or dulaglutide can effectively mitigate muscle atrophy in dexamethasone (Dex)-induced cellular and animal models as well as chronic kidney disease (CKD) and rodent sarcopenia models. However, it’s noteworthy that these agents may concurrently induce a decrease in body weight following administration, posing challenges when considering them as potential treatments for muscle atrophy in cachectic and sarcopenic conditions. Ghrelin, being the sole circulating orexigenic hormone known to be associated with growth hormone release, offers a potential solution to counterbalance the appetite-inhibiting effect of GLP-1R agonists. Additionally, ghrelin enhanced muscle anabolism and exerted protective effects for muscle atrophy. Therefore, combination of a GLP-1R agonist and a ghrelin analogue emerges as a synergistic therapeutic approach to effectively combat muscle atrophy.</p></div>","PeriodicalId":18425,"journal":{"name":"Medical hypotheses","volume":"189 ","pages":"Article 111418"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The synergistic potential of GLP-1R agonist dulaglutide and ghrelin receptor analogue anamorelin in ameliorating muscle atrophy\",\"authors\":\"Hla Myat Mo Mo , Jong Han Lee\",\"doi\":\"10.1016/j.mehy.2024.111418\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Muscle atrophy represents a multifaceted and intricate syndrome characterized by the reduction in both mass and strength of skeletal muscles, leading to muscle dysfunction and weakness. Its potential causes encompass aging, denervation, disuse, and various diseases. One well-known pharmacological agent for glycemic control in diabetes patients is the glucagon-like peptide-1 receptor (GLP-1R) agonist. Our recent research findings have shown that compounds such as exendin-4 (Ex-4) or dulaglutide can effectively mitigate muscle atrophy in dexamethasone (Dex)-induced cellular and animal models as well as chronic kidney disease (CKD) and rodent sarcopenia models. However, it’s noteworthy that these agents may concurrently induce a decrease in body weight following administration, posing challenges when considering them as potential treatments for muscle atrophy in cachectic and sarcopenic conditions. Ghrelin, being the sole circulating orexigenic hormone known to be associated with growth hormone release, offers a potential solution to counterbalance the appetite-inhibiting effect of GLP-1R agonists. Additionally, ghrelin enhanced muscle anabolism and exerted protective effects for muscle atrophy. Therefore, combination of a GLP-1R agonist and a ghrelin analogue emerges as a synergistic therapeutic approach to effectively combat muscle atrophy.</p></div>\",\"PeriodicalId\":18425,\"journal\":{\"name\":\"Medical hypotheses\",\"volume\":\"189 \",\"pages\":\"Article 111418\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical hypotheses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0306987724001610\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical hypotheses","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0306987724001610","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
The synergistic potential of GLP-1R agonist dulaglutide and ghrelin receptor analogue anamorelin in ameliorating muscle atrophy
Muscle atrophy represents a multifaceted and intricate syndrome characterized by the reduction in both mass and strength of skeletal muscles, leading to muscle dysfunction and weakness. Its potential causes encompass aging, denervation, disuse, and various diseases. One well-known pharmacological agent for glycemic control in diabetes patients is the glucagon-like peptide-1 receptor (GLP-1R) agonist. Our recent research findings have shown that compounds such as exendin-4 (Ex-4) or dulaglutide can effectively mitigate muscle atrophy in dexamethasone (Dex)-induced cellular and animal models as well as chronic kidney disease (CKD) and rodent sarcopenia models. However, it’s noteworthy that these agents may concurrently induce a decrease in body weight following administration, posing challenges when considering them as potential treatments for muscle atrophy in cachectic and sarcopenic conditions. Ghrelin, being the sole circulating orexigenic hormone known to be associated with growth hormone release, offers a potential solution to counterbalance the appetite-inhibiting effect of GLP-1R agonists. Additionally, ghrelin enhanced muscle anabolism and exerted protective effects for muscle atrophy. Therefore, combination of a GLP-1R agonist and a ghrelin analogue emerges as a synergistic therapeutic approach to effectively combat muscle atrophy.
期刊介绍:
Medical Hypotheses is a forum for ideas in medicine and related biomedical sciences. It will publish interesting and important theoretical papers that foster the diversity and debate upon which the scientific process thrives. The Aims and Scope of Medical Hypotheses are no different now from what was proposed by the founder of the journal, the late Dr David Horrobin. In his introduction to the first issue of the Journal, he asks ''what sorts of papers will be published in Medical Hypotheses? and goes on to answer ''Medical Hypotheses will publish papers which describe theories, ideas which have a great deal of observational support and some hypotheses where experimental support is yet fragmentary''. (Horrobin DF, 1975 Ideas in Biomedical Science: Reasons for the foundation of Medical Hypotheses. Medical Hypotheses Volume 1, Issue 1, January-February 1975, Pages 1-2.). Medical Hypotheses was therefore launched, and still exists today, to give novel, radical new ideas and speculations in medicine open-minded consideration, opening the field to radical hypotheses which would be rejected by most conventional journals. Papers in Medical Hypotheses take a standard scientific form in terms of style, structure and referencing. The journal therefore constitutes a bridge between cutting-edge theory and the mainstream of medical and scientific communication, which ideas must eventually enter if they are to be critiqued and tested against observations.